Targeted therapy for prostate cancer is a promising field, which is set to grow in the coming year. Here, Robert Jones, MD of the Beatson West of Scotland Cancer Centre, Glasgow, UK discusses the latest news in this area, including the ongoing Phase II trial of olaparib, TOPARP (NCT01682772), and the potential of PTEN-PI3K pathway inhibitors. This video was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK.
